



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 31/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/32932</b> <b>(43) International Publication Date:</b> 24 October 1996 (24.10.96)
<b>(21) International Application Number:</b> PCT/US95/09470 <b>(22) International Filing Date:</b> 26 July 1995 (26.07.95)  <b>(30) Priority Data:</b> 08/426,169 20 April 1995 (20.04.95) US  <b>(71) Applicant:</b> UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER [US/US]; 55 Lake Avenue North, Worcester, MA 01655 (US).  <b>(72) Inventors:</b> HERMANN, John, E.; Ten Newton Street, Northborough, MA 01532 (US). ROBINSON, Harriet, L.; Three Birchwood Drive, Southborough, MA 01772 (US). FYNAN, Ellen, F.; 13 Redstone Place, Sterling, MA 01564 (US).  <b>(74) Agents:</b> CLARK, Paul, T. et al.; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110 (US).	<b>(81) Designated States:</b> AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, ARIPO patent (KE, MW, SD, SZ, UG), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>	
<b>(54) Title:</b> DNA VACCINES AGAINST ROTAVIRUS INFECTIONS  <b>(57) Abstract</b>  This invention relates to DNA vaccines for eliciting an immune response and/or protective immunity in a vertebrate by introducing into the vertebrate the DNA vaccine which consists essentially of DNA encoding an antigen or antigens, e.g. capsid proteins or polypeptides, of rotavirus. The uptake of the DNA vaccine by a host vertebrate results in the expression of the capsid protein, thereby eliciting humoral or cell-mediated immune responses, or both, which can provide protection against infection and/or prevent clinically significant rotavirus-caused disease. In addition, the invention demonstrates that an internal viral antigen provides protective immunity in a host. The host can be any vertebrate, including birds, piglets, and humans.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## DNA VACCINES AGAINST ROTAVIRUS INFECTIONS

### Cross-Reference to Related Application

This application is a Continuation-in-Part of  
5 earlier filed (pending) U.S. Application Serial No.  
08/187,879, filed January 27, 1994, which is a  
Continuation-in-Part of (pending) U.S. Application Serial  
No. 08/009,833, filed January 27, 1993, which is a  
Continuation-in-Part of Application Serial No.  
10 07/855,562, filed March 23, 1992, now abandoned.

### Background of the Invention

Rotavirus infections are ubiquitous throughout  
mammalian and avian species. The viruses appear to be  
species-specific although cross-species infections can be  
15 produced experimentally and may occur in nature to a  
limited extent. Infection occurs after ingestion of  
viral particles and is restricted to the mature  
absorptive epithelial cells on the villi of the small  
intestine. Multiplication of rotaviruses within these  
20 cells results in lysis, and eventual loss of normal  
villous structure. Copious acute watery diarrhea occurs  
as a result of intestinal damage and replacement of  
absorptive cells by secreting cells from the villous  
crypts.

25 Viral gastroenteritis resulting from rotavirus  
infection is a common cause of epidemic diarrhea in  
infants from 6 to 24 months of age. Untreated rotavirus  
diarrhea in young children can be rapidly fatal. The  
recovery phase in some young children can be very  
30 protracted (involving villous atrophy associated with  
lactose intolerance) and can lead to or exacerbate  
existing malnutrition (Bishop, R.F. (1993) Vaccine  
11:247-254). In fact, rotaviruses appear to be  
responsible for at least one half of the cases of

- 2 -

infantile diarrhea that require hospitalization, and have been estimated to cause 500,000 to 1,000,000 human deaths worldwide each year.

Rotavirus has occasionally been reported as a  
5 cause of disease in military populations, in hospital workers, and as a cause of travelers' diarrhea. The most common setting for adult disease is that associated with parenting infected infants. Approximately 50% of parents experience rotavirus infection at the time of infant  
10 rotavirus disease; one-third of these adult infections are symptomatic (Offit, P.A. and Clark, H.F. (1995) In: *Principles and Practices of Infectious Diseases*, 4th ed., Mandell, G.L. et al., eds. pp. 1448-1455) and references cited therein). Moreover, rotaviruses are known to cause  
15 diarrhea in agriculturally valuable animals such as piglets, lambs, and foals, as well as in other animals such as rabbits, deer, and monkeys.

Currently, viral gastroenteritis therapy is limited to supportive measures, since there are no  
20 effective antiviral agents available for specific treatment. Prevention of rotavirus illness would be a major contribution to reduction of morbidity from gastroenteritis (Joklik, W.K., ed., *Virology*, 2nd. ed. (1985), Appleton-Century-Crofts, Norwalk, CT, pp. 236-  
25 238).

Vaccination with inactivated or attenuated organisms or their products has been shown to be an effective method for increasing host resistance and ultimately has led to the eradication of certain common  
30 and serious infectious diseases. The use of vaccines is based on the stimulation of specific immune responses within a host.

Rotavirus vaccine development began with tests in children using live, attenuated vaccines from animal  
35 rotavirus strains. Two candidate vaccines, RIT4237 and

- 3 -

WC3, both bovine serotype 6 viruses, have progressed to  
field trials (Estes, M.K. and Cohen, J. (1989),  
Microbiol. Rev. 53:410-449). The bovine strain RIT 4237  
showed good efficacy when tested initially in developed  
countries, but failed to provide protection when tested  
in developing countries, and has been removed from  
further testing (Estes, M.K. and Cohen, J. (1989),  
supra).

Effective vaccines have been developed for  
relatively few of the infectious agents that cause  
disease in domestic animals and man. This reflects  
technical problems associated with the growth and  
attenuation of virulent strains of pathogens.

Other approaches to the development of candidate  
vaccines include "reassortants," which contain a single  
gene encoding the outer capsid glycoprotein from human  
virus serotypes on a rhesus rotavirus background. Such  
reassortant vaccines have been produced as potential  
vaccines to induce homotypic immune response to the four  
human serotypes (Midthun et al., J. Virol. (1985) 53:949-  
954; and Estes M.K. and Cohen, J. (1989), supra).

Group A rotaviruses contain seven structural  
proteins. Of these, the two outer capsid proteins, VP4  
and VP7, appear to be the major proteins that induce  
humoral and cellular immune responses (Estes, M.R. and  
Cohen, J. (1989) supra; and Dharakul, R. et al. (1991) J.  
Virol. 65:5928-5932).

VP7 has been the subject of experimental vaccine  
studies because it is the most abundant outer capsid  
protein, accounting for approximately 30% of the total  
virion protein, compared to 1.5% for VP4 (Estes M.R. and  
Cohen, J. (1989), supra). However, inoculation with  
vaccinia or adenovirus recombinant virus containing a  
gene encoding a recombinant VP7<sub>sc</sub> gene, or a wild type SA-  
11 VP7 gene did not elicit protection against homologous

- 4 -

rotavirus challenge in an adult mouse model--(Dormitzer, P. et al. (1993) Abstr. IXth Intl. Congress of Virology, W21-2, p. 43; and Audio Tape, Dormitzer, P. et al. (August 10, 1993) IXth Intl. Congress of Virology, Workshop W21).).

The major component of the inner capsid, VP6, is antigenically conserved among different serotypes of group A rotaviruses infecting animals, birds, and humans (Bellamy A.R. and Both, G.W., Adv. Virus Res. (1990) 38:1-43; Estes, M. (1991) In: *Fundamental virology*, 2nd edn, Fields B.N. and Knipe, D.M., eds., pp. 619-642). VP6 is highly immunogenic and antigenic (Estes, M.R. and Cohen, J. (1989), *supra*) but, paradoxically, does not generate neutralizing antibodies when assayed in vitro. VP6 coding sequence cloned into a vaccinia virus vector and administered to adult mice did not protect against rotavirus infection (Dormitzer, P. et al. (1993) Abstr. IXth Intl. Congress of Virology, W21-2, p. 43; and Audio Tape, Dormitzer, P. et al. (August 10, 1993) IXth Intl. Congress of Virology, Workshop W21). Further, monoclonal antibodies to VP6 do not protect infant mice against rotavirus diarrhea (Riepenhoff-Talty, M. et al. (1987) Adv. Exp. Med. Biol. 216B:1015-1023).

#### Summary of the Invention

The invention relates to specific DNA vaccines and methods of providing protective immunity to vertebrates, particularly humans and pigs, against a rotavirus infection. "Protective immunity" conferred by the method of the invention can elicit humoral and/or cell-mediated immune responses to rotavirus infection, but more importantly interferes with the activity, spread, or growth of a rotavirus following a subsequent challenge after vaccination. The DNA vaccines of the invention are transcription units containing DNA encoding a

rotavirus polypeptide or protein. In the method of the present invention, a DNA vaccine is administered to an individual in whom protective immunization is desired.

An object of the invention is to provide an immune response and protective immunity to an animal using a DNA vaccine encoding a rotavirus protein as it has the potential of achieving high levels of protection in the virtual absence of side effects. Such DNA vaccines are also stable, easy to administer, and sufficiently cost-effective for widespread distribution.

An object of the invention is provide protective immunity to an inoculated host. If the inoculated host is a female animal, an object of the invention is to provide protection in the offspring of that female.

The invention features a DNA vaccine containing a rotavirus DNA transcription unit (i.e., an isolated nucleotide sequence encoding a rotavirus protein or polypeptide). The nucleotide sequence is operably linked to transcriptional and translational regulatory sequences for expression of the rotavirus polypeptide in a cell of a vertebrate. Preferably the rotavirus polypeptide encoded by the DNA vaccine of the invention is VP4, VP6, and/or VP7. Preferably, the nucleotide sequence encoding the rotavirus polypeptide is contained in a plasmid vector.

The DNA vaccines can be administered to mammals such as pigs or humans susceptible to rotavirus infection and rotavirus-caused disease.

The DNA vaccines of the invention are preferably contained in a physiologically acceptable carrier for in vivo administration to a cell of a vertebrate. Administration of the DNA vaccines of the invention provide an immune response or protective immunity in the vertebrate to disease caused by rotavirus infection.

- 6 -

Protective immunity is homologous, ~~homotypic~~, heterotypic, or heterotypic.

As used herein, the term "homotypic," referring to viral protection or viral challenge, means that the  
5 inoculating antigen and the challenge antigen are derived from the same viral serotype.

As used herein, the term "heterotypic," referring to viral protection or viral challenge, means that the inoculating antigen and the challenge antigen are derived  
10 from different viral serotypes.

As used herein, the term "homologous," referring to viral protection or viral challenge, means that the inoculating antigen and the challenge antigen are derived from rotaviruses having the same species specificity.

15 As used herein, the term "heterologous," referring to viral protection or viral challenge, means that the inoculating antigen and the challenge antigen are derived from rotaviruses having different species specificity.

The invention also features a DNA vaccine for use  
20 in, and a method for providing an immune response and protective immunity to a vertebrate against an infectious rotavirus. The method includes administering to a cell of a vertebrate a DNA transcription unit encoding a desired rotavirus antigen operably linked to a promoter  
25 sequence. Expression of the DNA transcription unit in the cell elicits a humoral immune response, a cell-mediated immune response, or both against the infectious rotavirus. The invention also features the use of a DNA vaccine for the manufacture of a medicament for providing  
30 an immune response and/or protective immunity. The medicament is made by standard techniques.

The promoter operably linked to the DNA transcription unit is of nonretroviral or retroviral origin. Preferably the promoter is the cytomegalovirus  
35 immediate-early enhancer promoter. The desired rotavirus



- 7 -

antigen encoded by the DNA transcription unit is VP4, VP6, and/or VP7.

Protective immunity provided by administration of the DNA transcription unit of the invention is homologous, homotypic, heterotypic, or heterologous. The infectious rotavirus can be of the same strain or the same serotype as the rotavirus from which the DNA encoding a desired antigen is obtained. Alternatively, the infectious rotavirus can be of a different strain, a different serotype, or different species specificity as the rotavirus from which the DNA encoding a desired antigen is obtained.

The method of providing an immune response and protective immunity is practiced on a vertebrate, preferably a mammal such as a pig or other animal. The vertebrate can also be a human susceptible to infection by rotavirus and susceptible to disease caused by rotavirus. The human may be an infant less than 3 years of age, human caring for an infected infant, or an immunocompromised human of any age.

The DNA transcription unit of the method of the invention is preferably formulated in a physiologically acceptable carrier and is administered to the vertebrate by routes including, but not limited to, inhalation, intravenous, intramuscular, intraperitoneal, intradermal, and subcutaneous administration. The DNA transcription unit in a physiologically acceptable carrier can also be administered by being contacted with a mucosal surface of the vertebrate.

Preferably, administration is performed by particle bombardment using gold beads coated with the DNA transcription units of the invention. Preferably, the gold beads are 1  $\mu\text{m}$  to 2  $\mu\text{m}$  in diameter. The coated beads are preferably administered intradermally, intramuscularly, by organ transfection, or by other

- 8 -

routes useful in particle bombardment and known to those of ordinary skill in the art.

The term "immune response" refers herein to a cytotoxic T cells response or increased serum levels of antibodies to an antigen, or to the presence of neutralizing antibodies to an antigen, such as a rotavirus protein. The term "protection" or "protective immunity" refers herein to the ability of the serum antibodies and cytotoxic T cell response induced during immunization to protect (partially or totally) against disease caused by an infectious agent, such as a rotavirus. That is, a vertebrate immunized by the DNA vaccines of the invention will experience limited growth and spread of an infectious rotavirus.

The term "promoter sequence" herein refers to a minimal sequence sufficient to direct transcription. Also included in the invention is an enhancer sequence which may or may not be contiguous with the promoter sequence. Enhancer sequences influence promoter-dependent gene expression and may be located in the 5' or 3' regions of the native gene. Expression is constitutive or inducible by external signals or agents. Optionally, expression is cell-type specific, tissue-specific, or species specific.

By the term "transcriptional and translational regulatory sequences" is meant nucleotide sequences positioned adjacent to a DNA coding sequence which direct transcription or translation of a coding sequence (i.e. facilitate the production of, e.g., VP4, VP6, or VP7 protein). The regulatory nucleotide sequences include any sequences which promote sufficient expression of a desired coding sequence (such as VP4, VP6, or VP7) and presentation of the protein product to the inoculated animal's immune system such that protective immunity is provided.

By the term "operably linked to transcriptional and translational regulatory sequences" is meant that a polypeptide coding sequence and minimal transcriptional and translational controlling sequences are connected in such a way as to permit polypeptide expression when the appropriate molecules (e.g., transcriptional activator proteins) are bound to the regulatory sequence(s). In the present invention, polypeptide expression in a target vertebrate cell is particularly preferred.

The term "isolated DNA" means DNA that is free of the genes and other nucleotide sequences that flank the gene in the naturally-occurring genome of the organism from which the isolated DNA of the invention is derived. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector; into an autonomously replicating plasmid or into the genomic DNA of a prokaryote or eukaryote; or which exists as a separate molecule (e.g., a cDNA or a genomic or cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequences.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described below. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the detailed description, and from the claims.

Brief Description of the Drawings

Fig. 1A is a schematic representation of control plasmid pCMV, a bacterial plasmid comprising a replication competent retroviral vector. The plasmid includes the CMV (cytomegalovirus) promoter/enhancer element and the rat preproinsulin gene.

Fig. 1B is a schematic representation of a plasmid referred to as the "pCMV/VP7 plasmid," which comprises a pCMV control plasmid and a rotavirus antigen DNA transcription unit encoding VP7 protein.

Fig. 2 is a bar graph depicting the cytotoxic T cell response of mice inoculated by gene gun with EDIM (Epizootic Diarrhea In Mice) VP7 rotavirus cDNA in comparison with controls. Solid bars represent an effector cell to target cell ratio of 60:1, and striped bars represent an effector cell to target cell ratio of 30:1.

Fig. 3 is a schematic representation of the pJW4303 plasmid comprising the CMV intron A, a leader sequence for the tissue plasminogen activator (TPA) protein, and bovine growth hormone polyadenylation sequences.

Fig. 4A is a schematic representation of control plasmid pCMVIA, a bacterial plasmid that includes the SV40 replication origin, the CMV immediate-early promoter/enhancer element, Intron A (the largest CMV intron), and a bovine growth hormone (BGH) gene that provides a polyadenylation signal. TPA is optionally removed for cloning purposes.

Fig. 4B is a schematic representation of the pCMVIA/VP7 plasmid, which includes the pCMVIA control plasmid and a rotavirus antigen DNA transcription unit encoding VP7 protein.

Fig. 5 is a graph showing protection against EDIM rotavirus challenge in immunized BALB/c mice. Mice were

inoculated with pCMVIA/VP7, control plasmid pCMVIA, or had been infected with EDIM virus one month prior to challenge. Fig. 6 is a bar graph showing the serum antibody responses to EDIM rotavirus in mice inoculated with the rotavirus itself, DNA vaccine pCMVIA/VP4, or control pCMVIA.

Fig. 7 is a graph showing the specificity of cytotoxic T cell (CTL) responses in pCMVIA/VP4-immunized BALB/c mice. Target cells (P815 cells) were infected with EDIM virus or coated with VP4 peptides at a concentration of  $30 \mu\text{M}/3 \times 10^6$  cells or  $3 \mu\text{M}/3 \times 10^6$  cells. The control cells were untreated P815 cells.

Fig. 8 is a graph showing protection against EDIM rotavirus challenge in immunized BALB/c mice. Mice were inoculated with pCMVIA/VP4, with control plasmid pCMVIA, or had been infected with EDIM virus one month prior to challenge.

Fig. 9 is a graph showing protection against EDIM rotavirus challenge in immunized BALB/c mice. Mice were inoculated with pCMVIA/VP6, control plasmid pCMVIA, or had been infected with EDIM virus one month prior to challenge.

Fig. 10 is a graph showing the specificity of CTL responses in pCMV/VP7 immunized BALB/c mice. Target cells (P815 cells) were infected with EDIM virus (solid squares); HSVI encoding SA11 rotavirus VP7 (open circles); or control HSVI (solid circles). The cell controls were untreated P815 cells (solid triangles).

Fig. 11 is a nucleotide sequence (SEQ ID NO:1) encoding a murine strain EW rotavirus VP4 protein.

Fig. 12 is a nucleotide sequence (SEQ ID NO:5) encoding a human rotavirus VP4 protein.

Fig. 13 is a nucleotide sequence (SEQ ID NO:2) encoding a human rotavirus VP6 protein.

Fig. 14 is a nucleotide sequence (SEQ ID NO:3) encoding a bovine rotavirus VP6 protein.

Fig. 15 is a nucleotide sequence (SEQ ID NO:4) encoding a murine strain EW VP7 protein.

5 Fig. 16 is a nucleotide sequence (SEQ ID NO:6) encoding a human rotavirus VP7 protein.

#### Detailed Description

This invention relates to a method of providing protective immunity to vertebrates, including humans, against rotavirus infection or disease caused by a rotavirus infection. Protective immunity of the invention elicits humoral and/or cell-mediated immune responses which interfere with the infectivity or activity of the rotavirus, or which limit its spread or growth, resulting in protection against subsequent challenge by the rotavirus. According to the present invention, a DNA transcription unit is administered to an individual in whom immunization and protection is desired.

#### 20 DNA Transcription Units

A DNA transcription unit is a polynucleotide sequence, bounded by an initiation site and a termination site, that is transcribed to produce a primary transcript. As used herein, a "DNA transcription unit" includes at least two components: (1) antigen-encoding DNA, and (2) a transcriptional promoter element or elements operatively linked for expression of the antigen-encoding DNA. Antigen-encoding DNA can encode one or multiple antigens, such as antigens from two or more different rotavirus proteins. The DNA transcription unit can additionally be inserted into a vector which includes sequences for expression of the DNA transcription unit.

- 13 -

10.01.01 A3 DNA transcription unit can optionally include additional sequences such as enhancer elements, splicing signals, termination and polyadenylation signals, viral replicons, and bacterial plasmid sequences. In the present method, a DNA transcription unit (i.e., one type of transcription unit) can be administered individually or in combination with one or more other types of DNA transcription units.

DNA transcription units can be produced by a number of known methods. For example, DNA encoding the desired antigen can be inserted into an expression vector (see, for example, Sambrook et al., Molecular Cloning, A Laboratory Manual, 2d, Cold Spring Harbor Laboratory Press (1989)). With the availability of automated nucleic acid synthesis equipment, DNA can be synthesized directly when the nucleotide sequence is known, or by a combination of polymerase chain reaction (PCR), cloning, and fermentation. Moreover, when the sequence of the desired polypeptide is known, a suitable coding sequence for the polynucleotide can be inferred.

The DNA transcription unit can be administered to an individual, or inoculated, in the presence of adjuvants or other substances that have the capability of promoting DNA uptake or recruiting immune system cells to the site of the inoculation. It should be understood that the DNA transcription unit itself is expressed in the host cell by transcription factors provided by the host cell, or provided by a DNA transcription unit.

The "desired antigen" can be any antigen or combination of antigens from a rotavirus. The antigen or antigens can be naturally occurring, or can be mutated or specially modified. The antigen or antigens can represent different forms, such as subgroups (clades), subtypes, or serotypes of rotavirus. These antigens may or may not be structural components of a rotavirus. The

- 14 -

encoded antigens can be translation products or polypeptides. The polypeptides can be of various lengths, and can undergo normal host cell modifications such as glycosylation, myristoylation, or phosphorylation. In addition, they can be designated to undergo intracellular, extracellular, or cell-surface expression. Furthermore, they can be designed to undergo assembly and release from cells.

Potential pathogens for which the DNA transcription unit can be used include DNA encoding antigens derived from any serotype or strain of rotavirus. It is to be understood that this list does not include all potential pathogens against which a protective immune response can be generated according to the methods herein described.

#### Administration of DNA Transcription Units

An individual can be inoculated through any parenteral route. For example, an individual can be inoculated by intravenous, intraperitoneal, intradermal, subcutaneous, inhalation, or intramuscular routes, or by particle bombardment using a gene gun. Muscle is a useful site for the delivery and expression of DNA transcription unit-encoded polynucleotides, because animals have a proportionately large muscle mass which is conveniently accessed by direct injection through the skin. A comparatively large dose of polynucleotides can be deposited into muscle by multiple and/or repetitive injections, for example, to extend therapy over long periods of time. Muscle cells are injected with polynucleotides encoding immunogenic polypeptides, and these polypeptides are presented by muscle cells in the context of antigens of the major histocompatibility complex to provoke a selected immune response against the



- 15 -

immunogen (see, e.g., Felgner, et al. WO90/11092, herein incorporated by reference).

The epidermis is another useful site for the delivery and expression of polynucleotides, because it is conveniently accessed by direct injection or particle bombardment. A comparatively large dose of polynucleotides can be deposited in the epidermis by multiple injections or bombardments to extend therapy over long periods of time. In immunization strategies of the invention, skin cells are injected with polynucleotides coding for immunogenic polypeptides, and these polypeptides are presented by skin cells in the context of antigens of the major histocompatibility complex to provoke a selected immune response against the immunogen.

In addition, an individual can be inoculated by a mucosal route. The DNA transcription unit can be administered to a mucosal surface by a variety of methods including DNA-containing nose-drops, inhalants, suppositories, microsphere encapsulated DNA, or by bombardment with DNA coated gold particles. For example, the DNA transcription unit can be administered to a respiratory mucosal surface, such as the nares or the trachea.

Any appropriate physiologically compatible medium, such as saline for injection, or gold particles for particle bombardment, is suitable for introducing the DNA transcription unit into an individual.

Immunization as described herein was accomplished with various DNA transcription units encoded on plasmid vectors that express different rotavirus proteins. The DNA transcription units described herein are representative of the types of transcription units that can be used in the current invention. The DNA transcription units can encode antigens from a single

rotavirus species, including antigens from different subgroups (clades) or subtypes of the specie, and can additionally encode antigens from more than one rotavirus species.

5           Rotavirus DNA Transcription Units

In one embodiment of the current invention, immunization was accomplished using a DNA transcription unit encoding either of two murine rotavirus neutralizing capsid proteins, VP4 (SEQ ID NO:1; Fig. 11) or VP7 (SEQ  
10 ID NO:4; Fig. 15), or the internal core protein, VP6. DNA expression plasmids for the VP4, VP6, and VP7 protein were used to provide protection against challenge with an infectious rotavirus. An adult mouse model first  
described in Ward et al., *J. Virol.*, 64:5070-5075 (1990)  
15 (incorporated herein by reference) was used to test for protection.

The adult mouse model is convenient in assessing protection against an infectious agent by increasing the time period within which to perform the study. In this  
20 model, adult BALB/c mice (6 weeks or older) inoculated with a rotavirus do not show disease symptoms but, instead, exhibit infection as viral shedding in the feces for approximately one week post-infection. Virus  
shedding in feces is conveniently measured and  
25 quantitated by ELISA. Studies involving quantitation of viral shedding in adult mice is preferred over studies in which disease symptoms are observed in infant mice because the latter studies are hindered by the short  
period in which infant mice are susceptible to rotavirus  
30 illness (from birth to 15 days of age).

In the systemic strategies presented herein, an effective DNA dosage will generally be in the range of about 1  $\mu$ g/kg to about 50  $\mu$ g/kg, preferably about 10-25  $\mu$ g/kg of body weight of the animal. However, as will be

- 17 -

appreciated, this dosage will vary in a manner apparent to those of ordinary skill in the art according to the particular DNA used, the particular polypeptide encoded by the DNA, and the vertebrate being inoculated. For delivery of VP4, VP6, or VP7 to a vertebrate, such as a mouse, for example, adequate levels of translation are achieved with a DNA dosage of about 20  $\mu\text{g/kg}$  of mouse body weight (see Example 3). From this information, dosages for other immunogenic polypeptides and other vertebrates, such as a pig or human, can be readily determined.

The following Examples describe vaccination trials using direct DNA inoculations designed for use in rotavirus immunoprotection. Vaccination trials for rotavirus were conducted using an adult mouse model. The adult mouse model demonstrated antibody and cytotoxic T-cell activity in animals inoculated with DNA transcriptional units for rotavirus protein, wherein animals inoculated with control DNA exhibited no antibody or cytotoxic T-cell activity for rotavirus. Protective immunity was also observed when the adult mice immunized with the DNA vaccine of the invention were subsequently challenged with rotavirus.

The current invention is illustrated by the following examples, which are not to be construed as limiting in any way.

#### EXAMPLES

##### Example 1: DNA Constructs for Immunization of Mice Using a DNA Transcription Unit Encoding a Rotavirus Protein

A plasmid construct referred to as pCMV/VP7 places cDNA for murine rotavirus capsid protein, VP7 (SEQ ID NO:4), under the transcriptional control of the human CMV (cytomegalovirus) immediate-early enhancer/promoter

- 18 -

element and the rat preproinsulin II gene. The pCMV plasmid without a rotaviral insert is a derivative of the pBC12/CMV plasmid of Dr. Bryan Cullen, Duke University, Durham, North Carolina as described in Cullen, B.R., Cell 5 45:973-982 (1986).

The pCMV/VP7 plasmid expresses VP7, a murine rotavirus neutralization capsid protein. VP7 cDNA (SEQ ID NO:4) from EDIM EW strain murine rotavirus was obtained from Dr. Harry Greenberg, Stanford University, 10 Stanford, CA, USA (Dunn, S.J. et al. (1994) *Virology* 203:250-269; and can be obtained using standard techniques based on the complete sequence disclosed herein (SEQ ID NO:4) and in GenBank accession number U08430). For the purpose of the experiments described 15 herein, murine VP7 cDNA (SEQ ID NO:4) was inserted between the *Bam*HI and *Hind*III sites of the pCMV/control vector in an orientation for expression of the VP7 coding sequence. Another source of VP7 coding sequence is from porcine rotavirus VP7 (Gorziglia, M. et al. (1988) *Nucl.* 20 *Acids Res.* 16:775).

#### Example 2: Immunizations by Intradermal Particle Bombardment Delivery of DNA to Mice

Intradermal administration of DNA by particle bombardment was used to deliver DNA for expression of a 25 rotavirus gene in skin cells. The Accell particle bombardment device ("gene gun"; Agracetus, Middleton, WI) was employed to deliver DNA-coated gold beads to the epidermis of mice.

Plasmid DNA was affixed to gold particles by 30 adding 10 mg of 0.95  $\mu$ m gold powder (Degussa, South Plainfield, NJ), and an appropriate amount of plasmid DNA, to a 1.5-ml centrifuge tube containing 50  $\mu$ l of 0.1 M spermidine. Plasmid DNA and gold were co-precipitated by the addition of 50  $\mu$ l of 2.5 M  $\text{CaCl}_2$  during vortex

- 19 -

mixing, after which the precipitate was allowed to settle and was washed with absolute ethanol and resuspended in 2.0 ml of ethanol. The gold/DNA suspension was transferred to a capped vial and immersed in a sonicating water bath for 2-5 seconds to resolve clumps. The 163  $\mu$ l of the gold/DNA suspension was layered onto 1.8 cm x 1.8 cm Mylar sheets and allowed to settle for several minutes after which the meniscus was broken and excess ethanol was removed by aspiration. Gold/DNA-coated mylar sheets were dried and stored under vacuum. The total amount of DNA per sheet was a function of the DNA/gold ratio and ranged from 0.2 to 0.0002  $\mu$ g per sheet.

Animals were anesthetized with 30  $\mu$ l of Ketaset/Rompun (10:2). Abdominal target areas were shaved and treated with Nair (Carter-Wallace, New York) for two minutes to remove residual stubble and stratum corneum. Target areas were thoroughly rinsed with water prior to gene delivery. DNA-coated gold particles were delivered into abdominal skin with the Accell instrument, which employs an electric spark discharge as the motive force. Each animal received two nonoverlapping deliveries per immunization, at a discharge voltage of 17 kV. Particle bombardment technology is presented in the following articles, herein incorporated by reference:

Yang, M.S. et al., (1990) Proc. Natl. Acad. Sci. USA 87:9568-9572; Yang N.-S. (1992) CRC Crit. Rev. Biotechnol. 12:335-356; and Cheng, L. et al. (1993) Proc. Natl. Acad. Sci. USA 90:4455-4459.

The beads deliver DNA into cells, where the DNA dissolves and can be expressed (Yang, M.S. et al. (1991) Proc. Natl. Acad. Sci. USA 88: 2726-2730). Expression is transient, with most of the expression being lost within 2-3 days due to the normal sloughing of the epidermis (Williams, R.S. et al., Proc. Natl. Acad. Sci. USA 88: 2726-2730 (1991)).

These particle bombardment techniques can be easily adapted for use in human patients using human rotavirus DNA vaccines as described below.

Example 3: Inducing an Immune Response in Mice Using the

5 pCMV/VP7 Plasmid

A rotavirus DNA transcription unit was tested for its ability to induce an immune response in mice. The pCMV/VP7 plasmid and the control plasmid used in this experiment to vaccinate mice against rotavirus are  
10 depicted in Figs. 1A and 1B.

The DNA vaccine pCMV/VP7 construct was inoculated into BALB/c (H-2<sup>d</sup>) mice by gene gun delivery of DNA-coated gold beads into the epidermis as described above. The dose given was 0.4 µg of DNA per mouse. This dose  
15 was previously determined to be optimal for DNA vaccination against influenza virus in mice (Fynan, E.F. et al. (1993) PNAS USA 90:11478-11482). Two inoculations were given at 4-week intervals. The boosts used the same DNA dose and sites of inoculation as the vaccinations.  
20 Mice were tested for serum antibody levels and CTL responses 2 to 4 weeks after the second inoculation.

Serum antibody levels were determined by ELISA against EDIM rotavirus (Epizootic Diarrhea In Mice) for mice receiving EDIM strain EW virus VP7 DNA (as pCMV/VP7)  
25 or control DNA (as pCMV). Six mice were tested per group. The neutralization assay was performed as described in Dunn, S.J. et al. (1994), supra. The EDIM strain EW virus was obtained from H.B. Greenberg, Stanford University, Stanford, CA, USA. Age-matched mice  
30 were inoculated with pCMV/VP7 DNA or pCMV/control DNA using the gene gun as described above or were administered live EDIM virus by oral gavage at a dosage of 100 ID<sub>50</sub>/mouse. The relative antibody production in

- 21 -

adult mice following inoculation of the DNA vaccine and a live virus are compared in Table 1.

TABLE 1

## Serum Anti-VP7 Antibody Titers Following Inoculation

5 [Mean Antibody Titer]<sup>-1</sup>

Inoculum	Preinoculation		4 weeks Postinoculation	
	ELISA	Neutralization	ELISA	Neutralization
pCMV/VP7	<50	<50	400	100
pCMV/control	<50	<50	<50	<50
10 EDIM virus	<50	<50	800	200

The results in Table 1 show that serum antibody to EDIM virus developed only in mice receiving the plasmid containing the wild-type VP7 coding sequence (SEQ ID NO:4) or live EDIM virus. The titers obtained in sera  
15 taken at one month after the second DNA inoculation were 1:200 in mice receiving pCMV/VP7 and 1:800 in mice inoculated with EDIM virus. Antibody titers remained below 1:50 in mice inoculated with the control DNA.

It was also found that plasmid pCMV/VP7 was able  
20 to induce a cytotoxic T cell (CTL) response against murine rotavirus-infected cells. Cellular immune response was determined by measuring CTL activity in adult mice which were vaccinated with pCMV/VP7 or were given EDIM virus, as was done for the induction of serum  
25 antibodies in Example 2. Memory CTL activity was measured after in vitro stimulation. Splenic lymphocytes from DNA-treated or EDIM-infected mice were stimulated in vivo with EDIM virus. The activity of these effector lymphocytes was measured by a standard chromium-release  
30 CTL assay. EDIM-infected P815 (H-2<sup>d</sup>) cells were used as target cells (P815 (H-2<sup>d</sup>) cells may be obtained from ATCC as TIB 64). Separate experiments were performed in which effector cell to target cell (E:T) ratios were 60:1

- 22 -

(filled bars) or 30:1 (striped bars) as shown in Fig. 2. The results using the two different E:T ratios indicate that increasing the number of total cells increases the number of effector cells contacted with the target cells in the CTL chromium-release assay. Thus, the 60:1 E:T experiment shows increased response relative to the 30:1 E:T ratio.

The memory CTL activity of mice inoculated with pCMV/VP7 was approximately 30% at an effector to target ratio of 60:1, compared to 45% lysis obtained with mice orally infected with EDIM rotavirus indicating an effective response to both the DNA vaccine and the EDIM virus. The low level of activity seen with the control DNA may be due to non-specific stimulation of natural killer cells by the plasmid vector. There was minimal lysis of uninfected target cells by the effector cells.

Example 4: Protective Immunity Against Homotypic Rotavirus Challenge Induced by Inoculation with the pCMVIA/VP7 Plasmid

Initial experiments in mice inoculated with pCMV/VP7 did not show protection when challenged with EDIM virus strains EW at a concentration of  $10^2$  adult ID<sub>50</sub>/ml, even though the vaccine induced an immune response as determined by the presence of neutralizing serum antibody and CTL responses.

Surprisingly, protection by VP7 against homotypic rotavirus challenge as well as induction of antibody response was shown using a different plasmid vector, JW4303 shown in Fig. 3 (Dr. J. Mullins, University of Washington, Seattle, WA USA). The vector encodes a CMV promoter/enhancer element and also encodes intron A upstream of the rotavirus cDNA site of insertion. The presence of intron A (IA) positively regulates expression of the insert cDNA from the CMV immediate-early



s. ~~plasmid~~ promoter/enhancer element in mammalian cell lines  
(Chapman, B.S., et al. (1991) Nucleic Acids Research  
19:3979-3986). Figs. 4A and 4B are diagrams showing the  
control plasmid (pCMVIA) and the plasmid containing a VP7  
(SEQ ID NO:4) insert (pCMVIA/VP7). The bovine growth  
hormone (BGH) gene sequence provides polyadenylation  
signals necessary for expression.

The ability of the pCMVIA/VP7 DNA vaccine to  
provide protective immunity against homotypic virus  
challenge was demonstrated in the adult mouse model.  
Protection is determined by the quantitation of virus  
shedding in feces of inoculated mice following viral  
challenge.

The results in Fig. 5 show that mice which  
received the control plasmid pCMVIA showed no protection  
against challenge virus (filled circles). Mice which  
received the pCMVIA/VP7 DNA vaccine (open circles; two  
inoculations at a 4 week interval) showed homotypic  
protection at 4 weeks following the second inoculation.  
This result is similar to that obtained in mice which had  
received a single oral inoculation with EDIM virus 4  
weeks prior to analysis (open squares).

Example 5: Protective Immunity Against Homotypic  
Rotavirus Challenge Induced by Inoculation with the  
25 pCMVIA/VP4 DNA Vaccine

The cDNA of murine strain EW rotavirus VP4 (SEQ ID  
NO:1; Dunn, S.J. et al. (1994) Virology 203:250-269;  
GenBank accession number U08429) was inserted into the  
pCMVIA plasmid between the *Bam*HI and *Hind*III sites in the  
30 orientation for expression of the VP4 gene under the  
control of the CMV immediate-early promoter/enhancer  
element and the intron A sequence. Other sources of VP4  
coding sequence include human rotavirus VP4 (Taniguchi,  
K. et al. (1988) J. Virol. 62:2421-2426; GenBank

- 24 -

accession number M21014; Fig. 127 SEQ ID NO:3) and porcine rotavirus VP4 (Nishikawa, K. and Gorziglia, M. (1988) Nucl. Acids Res. 16:11847; GenBank accession number X13190).

- 5 BALB/c (H-2<sup>d</sup>) adult mice were inoculated with 0.4  $\mu$ g of pCMVIA/VP4 DNA by gene gun delivery into the epidermis as was performed for the VP7 experiments above. For comparison, mice were inoculated with control plasmid vector or with live EDIM virus. Inoculated mice were
- 10 tested for anti-VP4 antibodies in serum by the ELISA assay and rotavirus neutralizing antibodies in serum at 4 weeks following the second inoculation of plasmid or virus. The results shown in Fig. 6 indicate that EDIM virus and the pCMVIA/VP4 plasmid stimulated antibody
- 15 responses, whereas no rotavirus-specific responses were seen in the mice inoculated with the plasmid control.

- Cellular immune response was tested by examining memory CTL activity of splenic lymphocytes from pCMVIA/VP4 immunized mice. To test for VP4 specificity,
- 20 P815 target cells were passively coated by incubation with VP4 peptides. The VP4 peptides were synthesized from a sequence published in Shimojo, N. et al. (1989) J. Immunol. 143:2939-2947, and prepared by the peptide synthesis facility at the University of Massachusetts
- 25 Medical Center using standard synthetic techniques. The results of these assays are shown in Fig. 7. CTL activity of lymphocytes (effector cells) from mice inoculated with pCMVIA/VP4 was measured. The target cells were uninfected P815 target cells (open triangles),
- 30 P815 target cells infected with EDIM virus (solid diamonds) or coated with VP4 peptide (at a concentration of 30  $\mu$ M/3x10<sup>6</sup> cells (solid circles) or 3  $\mu$ M/3x10<sup>6</sup> cells (open circles). The results show that inoculation of mice by DNA vaccine pCMVIA/VP4 produced cytotoxic
- 35 activity against target cells infected with EDIM virus or

coated with VP4 protein (at  $30 \mu\text{M}$  VP4/ $3 \times 10^6$  cell). There was essentially no cytotoxic activity against P815 control cells and cells coated with VP4 protein at  $3 \mu\text{M}$  VP4/ $3 \times 10^6$  cells. Providing another positive control, lymphocytes from mice infected with EDIM virus were found to exhibit CTL responses to the VP4-coated cells (data not shown).

The ability of the pCMVIA/VP4 DNA vaccine to provide protection against homotypic rotavirus challenge was demonstrated in adult mice by the same procedure as for VP7 in Example 4. The results showing the protective immunity against homotypic rotavirus infection induced by VP4 are shown in Fig. 8. Protection is measured by a reduction in virus shedding monitored by ELISA to be less than  $0.1 A_{492}$  units. Both the pCMVIA/VP4 DNA vaccine (open circles) and the live EDIM virus (open squares) provided protection against EDIM viral challenge as indicated by mean  $A_{492}$  values less than 0.1 for 14 days post challenge. However, the pCMVIA control plasmid (filled circles) did not provide protection as indicated by  $A_{492}$  values greater than 0.1 from 1 to 7 days post challenge.

Example 6: Protective Immunity Against Homotypic Rotavirus Challenge Induced by Inoculation with the pCMVIA/VP6 DNA Vaccine

The cDNA of murine EDIM strain EW rotavirus VP6 cDNA (obtained from H. Greenberg, Stanford University, *supra*) was inserted into the pCMVIA plasmid between the *Bam*HI and the *Hind*III in the orientation for expression of the VP6 gene under the control of the CMV immediate-early promoter/enhancer element and the intron A sequence. The cDNA encoding murine rotavirus VP6 coding sequence can be isolated by deriving probes and/or PCR primers from any of the following nucleotide sequences as

- 26 -

well as other rotavirus VP6 sequences: human rotavirus VP6 (SEQ ID NO:2, Palombo, E.A. and Bishop, R.F. (1993), GenBank accession number U04741; Fig. 13); bovine rotavirus VP6 (SEQ ID NO:3, Fig. 14; Tarlow, O. and McCrae, M.A. (1990) Nucl. Acids Res. 18:4921).

Techniques for such isolation and/or PCR amplification are well known to those of ordinary skill in the art (see e.g., Sambrook, J. et al. *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratories (1989))

10 A pCMVIA plasmid containing a murine rotavirus gene encoding VP6, the internal rotavirus group antigen, demonstrated protective immunity against EDIM viral challenge using the same procedure used to test VP7 and VP4. A graph of pCMVIA/VP6-induced protective immunity  
15 to homotypic rotavirus challenge is shown in Fig. 9. Protection is measured by a reduction in virus shedding monitored by ELISA to be less than 0.1  $A_{492}$  units. Both the pCMVIA/VP6 DNA vaccine (open circles) and the live EDIM virus (open squares) provided protection against  
20 EDIM viral challenge as indicated by mean  $A_{492}$  values less than 0.1 for 14 days post challenge. However, the pCMVIA control plasmid (filled circles) did not provide protection as indicated by  $A_{492}$  values greater than 0.1 from 1 to 7 days post challenge. Thus, a similar degree  
25 of protection was obtained with the pCMVIA/VP6 DNA vaccine as seen for the VP4 and VP7 DNA vaccines.

This was a surprising result because the pCMVIA/VP6 construct did not elicit neutralizing antibodies and because protection by VP6 administration  
30 had not previously been shown. On the contrary, direct inoculation of VP6 had been shown not to be involved in protective immunity to EDIM challenge despite the apparent induction of antibody titers (Dormitzer, P. et al. Audio Tape (August 10, 1993) IXth Intl. Congress of  
35 Virology, Workshop W21; Estes, M.K. and Cohen, J. (1989),

Microbiol. Rev. 53:410-449; and Riepenhoff-Talty, M. et al. (1987) Adv. Exp. Med. Biol. 216B:1015-1023).

Previously, both a VP6 and a recombinant VP7 (VP7<sub>sc</sub>) encoded in a vaccinia virus or adenovirus vector did not elicit protective immunity (Audio Tape, Dormitzer, P. et al. (August 10, 1993) IXth Intl. Congress of Virology, Workshop W21). The VP6 protein, expressed from pCMVIA/VP6 in a vertebrate cell, is shown for the first time to induce protective immunity to a rotavirus challenge even though no neutralizing antibodies were elicited. In fact, a DNA vaccine of the invention encoding a wild type inner core VP6 protein offers similar protection to the DNA vaccines encoding the outer capsid proteins VP4 or VP7 as described herein.

15 Example 7: Heterologous Immune Response Induced by pCMV/VP7 DNA Vaccine

The ability of EDIM strain EW-derived VP7 DNA vaccine to elicit an immune response to VP7 from rotaviruses of the same (homologous) or different (heterologous) species specificities was demonstrated. Target cells infected with EDIM strain EW virus (homologous test) or with herpes simplex virus (HSV) encoding simian (SA-11) rotavirus VP7 (Dormitzer, P.R. et al. (1994) Virology 204:391-402) (heterologous test) were tested for lysis by effector cells from mice inoculated with EDIM virus or with pCMV/VP7 DNA vaccine. The results are shown in Fig. 10. Lymphocytes from mice which had been inoculated with pCMV/VP7 showed CTL activity against P815 target cells infected with HSV expressing rotavirus strain SA-11 VP7 (open circles) as well as target cells infected with EDIM virus (closed squares). The percent specific lysis of target cells infected with EDIM virus or HSVI/SA-11 was approximately 35% and 20%, respectively, using effector cells from the

- 28 -

5 pCMV/VP7 immunized mice at an E:T ratio of 60:1. Low background levels of CTL activity was observed against control P815 cells and P815 cells infected with HSV without a rotavirus encoded protein. Induction of CTL activity by pCMV/VP7 shows that the VP7 protein of one rotavirus serotype A strain can induce an immune response against the VP7 protein of another rotavirus serotype A strain.

Example 8: Heterotypic and Heterologous Protective

10 Immunity Induced by pCMVIA/VP4, pCMVIA/VP6, and pCMVIA/VP7

Heterotypic protection by VP4, VP6, and VP7 is demonstrated by inoculating mice with a pCMVIA/VP4, pCMVIA/VP6, or pCMVIA/VP7 DNA vaccine by the procedure  
15 described in the examples above. Each of these DNA vaccines encodes a rotavirus protein derived from EDIM strain EW rotavirus. Following inoculation, the mice are challenged with a rotavirus strain which is heterologous or heterotypic relative to the rotavirus from which the  
20 VP4, VP6, or VP7 cDNA was derived.

Heterologous challenge is demonstrated by inoculating the mice with a DNA vaccine encoding VP4, VP6, or VP7 from a non-murine source (e.g., simian SA-11 or other non-murine rotavirus VP4, VP6, or VP7) followed  
25 by challenge with murine rotavirus by the procedures described in previous examples.

Following challenge, viral shedding is quantitated by ELISA and heterotypic protection is determined to be an ELISA value lower than 0.1 A<sub>492</sub> units. Control  
30 inoculation and homotypic challenge is performed in parallel to compare the relative degrees of protection.

The information gained by using an adult mouse model to assess vaccine effectiveness (as reduction in virus shedding) is a useful measure of effectiveness in

larger vertebrates (Ward, R.L. et al. (1990) J. Virol. 64:5070-5075). Chronic viral shedding by adult cattle and swine is a reservoir for persistence of rotavirus between epidemics (Goto, Y. et al. (1986) Vet. Microbiol. 11:177-184; and Banfield, D.A. et al. (1982) J. Clin. Microbiol. 16:186-190) and is said to be true for humans (Offit, P.A. (1995) supra).

Example 9: A Method of Providing Protective Immunity Against Rotavirus in Swine

10 To provide protection against rotavirus infection in swine, a DNA vaccine encoding a porcine rotavirus protein is constructed. cDNA from a porcine rotavirus VP4 (Nishikawa and Gorziglia (1988), supra; GenBank accession number X13190), VP6 (Gonzalez, S.A. et al. 15 (1995) J. Gen. Virol. 76:221-224), or VP7 (Gorziglia et al. (1988), supra; GenBank accession number X04613) is inserted in the pCMVIA plasmid as for the murine DNA vaccine constructs described above. Optionally, heterologous protection can be provided by administering 20 a vaccine constructed using VP4, VP6, or VP7 from a rotavirus of different species specificity.

The DNA vaccine is administered to the animal by several routes selected from the following: intravenous, intramuscular, intraperitoneal, intradermal, inhalation, 25 and subcutaneous administration. For example, intradermal administration by particle bombardment is a preferred route. The site of administration is chosen for the convenience of the administrator. Suckling pigs are inoculated by intradermal particle bombardment 30 delivery of gold beads coated with the pCMVIA plasmid vector containing VP4, VP6, or VP7 cDNA from porcine or other species-specific rotavirus strains. The dose is between 1 and 50  $\mu$ g of DNA vaccine per kg body weight of the pig, preferably 10-25  $\mu$ g per kg body weight.

- 30 -

Inoculations are given at 4 week intervals until the animal is provided with long term cellular immune response.

Protection is determined by challenging the inoculated pigs with porcine rotavirus from the same serotype and the same or different strain. Virus shedding is monitored by standard techniques known to those of ordinary skill in the art and disease symptoms such as diarrhea are monitored relative to an uninoculated pig.

Example 10: A Method of Providing Protective Immunity Against Rotavirus in Humans

Rotavirus serogroups A, B, and C are known to cause severe gastroenteritis in humans. Human infants (from 6 to 24 months of age), adults parenting infected infants, elderly humans, and immunocompromised humans of any age are susceptible to developing disease upon infection with rotavirus. To provide protection in humans against rotavirus infection, a DNA vaccine encoding a human rotavirus protein is constructed. cDNA from the human rotavirus VP4 (Taniguchi, (1988), supra; GenBank accession number M21014; Fig. 12), VP6 (SEQ ID NO:2; Fig. 13), or VP7 (Dyall-Smith, M.L., WO 8901514-A; GenBank accession number A01321; Fig. 16; SEQ ID NO:6) is inserted in the pCMVIA plasmid as for the murine DNA vaccine constructs described above. Optionally, heterologous protection can be provided by administering a vaccine constructed using VP4, VP6, or VP7 from a rotavirus of different species specificity.

Administration of a DNA vaccine to a human can be performed by any one or more of several routes selected from the following: intravenous, intramuscular, intraperitoneal, intradermal, inhalation, and subcutaneous. For example, intradermal administration by



- 31 -

gene gun is a preferred route. The site of administration is chosen for the convenience of the patient. A human patient is inoculated with the human rotavirus-derived pCMVIA/VP4, pCMVIA/VP6, or pCMVIA/VP7 DNA vaccine by gene gun delivery of DNA-coated gold beads. The dose is between 1 and 50  $\mu$ g of DNA vaccine per kg body weight, preferably 10-25  $\mu$ g per kg body weight. For a human infant, two inoculations are given at a 4 week interval. A human of any age who is caring for an infected infant or is immunocompromised due to illness, drug treatment, or other cause putting him or her at risk of rotavirus infection is inoculated with the DNA vaccine by gene gun delivery for at least 2 inoculations at 4 week intervals.

Mucosal routes of DNA inoculation involve the administration of microsphere-encapsulated DNA to raise protective responses against a rotavirus challenge. pCMVIA/VP4, pCMVIA/VP6, or pCMVIA/VP7 DNA can be encapsulated in microspheres. Each patient receives a primary inoculation and a boost. The patients receive approximately 1-50  $\mu$ g/kg body weight of microsphere-encapsulated DNA for both the primary and boost inoculations. Each administration of encapsulated DNA is delivered in 100  $\mu$ l of water intranasally.

#### Use

Rotavirus disease in human infants and adults occurs worldwide and is responsible for the hospitalization and even the death of many patients. Disease caused by rotavirus in animals, such as pigs, results in significant losses in agricultural revenue each year. Thus, a safe, effective vaccine that protects against infection by rotavirus is important in both human and verterinary medicine.

- 32 -

A human rotavirus DNA vaccine of the invention is useful in providing protection against rotavirus infection in human infants, caretakers of infected infants, and immunocompromised humans. A porcine DNA vaccine of the invention is useful to prevent rotavirus infection in piglets thereby allowing the animals to thrive for increased agricultural benefit. A DNA vaccine against any human or animal rotavirus can be constructed and used according to the invention. Such vaccines are useful in providing homologous protection against a specific strain of rotavirus. The DNA vaccine of the invention is also useful in providing heterologous protection in that a DNA vaccine derived from one species-specific rotavirus, serotype, or strain can be used to induce protective immunity against a rotavirus from a different species-specific rotavirus, serotype, or strain.

Broad protection against multiple strains within a given serotype is possible according to the invention by inoculating the human or animal with a DNA vaccine encoding a protection-inducing protein from a rotavirus strain of the same serotype. Thus, a single DNA vaccine of the invention is useful in providing protection against multiple strains of rotavirus (see Example 8, above).

The DNA vaccine of the invention is also useful for diagnosis of rotavirus infection. Virus particles from stool of the patient or infected animal are contacted with serum of an animal, such as a mouse, which has been inoculated with a known serotype, species-specific DNA vaccine of the invention. Viral neutralization by the serum antibodies or other type-specific assays informs the clinician as to the disease-causing rotavirus serotype.

Other Embodiments

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, that the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

What is claimed is:

Claims of Patent

1. DNA vaccine consisting essentially of a plasmid vector and one or more isolated nucleotide sequences each encoding a rotavirus polypeptide, and  
5 transcriptional and translational regulatory sequences operably linked to the isolated nucleotide sequences for expression of the rotavirus polypeptide in a cell of a vertebrate.
2. DNA vaccine of claim 1, wherein the regulatory  
10 sequences comprise CMV immediate-early promoter and intron A.
3. DNA vaccine for use in eliciting an immune response against a rotavirus in a vertebrate, said DNA vaccine consisting essentially of a plasmid vector and  
15 one or more isolated nucleotide sequences each encoding a rotavirus polypeptide, and transcriptional and translational regulatory sequences operably linked to the isolated nucleotide sequences, whereby expression of said nucleotide sequences in a vertebrate cell elicits a  
20 humoral immune response, a cell-mediated immune response, or both, against the rotavirus.
4. The use of a DNA vaccine for the manufacture of a medicament for use in eliciting an immune response against a rotavirus in a vertebrate, said DNA vaccine  
25 consisting essentially of a plasmid vector and one or more isolated nucleotide sequences each encoding a rotavirus polypeptide, and transcriptional and translational regulatory sequences operably linked to the isolated nucleotide sequences, whereby expression of said  
30 nucleotide sequences in a vertebrate cell elicits a

humoral immune response, a cell-mediated immune response, or both, against the rotavirus.

5. DNA vaccine for use in eliciting a protective immunity against a rotavirus infection in a vertebrate,  
5 said DNA vaccine consisting essentially of a plasmid vector and one or more isolated nucleotide sequences each encoding a rotavirus polypeptide, and transcriptional and translational regulatory sequences operably linked to the isolated nucleotide sequences, whereby expression of said  
10 nucleotide sequences in a vertebrate cell elicits a humoral immune response, a cell-mediated immune response, or both against the rotavirus in the vertebrate, and whereby the vertebrate is protected from disease caused by subsequent exposure to the rotavirus.

15 6. The use of a DNA vaccine for the manufacture of a medicament for use in eliciting a protective immunity against a rotavirus infection in a vertebrate, said DNA vaccine consisting essentially of a plasmid vector and one or more isolated nucleotide sequences each  
20 encoding a rotavirus polypeptide, and transcriptional and translational regulatory sequences operably linked to the isolated nucleotide sequences, whereby expression of said nucleotide sequences in a vertebrate cell elicits a humoral immune response, a cell-mediated immune response,  
25 or both against the rotavirus in the vertebrate, and whereby the vertebrate is protected from disease caused by subsequent exposure to the rotavirus.

- 36 -

7. A DNA vaccine of claim 1, 5, or 6, wherein the regulatory sequences are of nonretroviral origin.

8. A DNA vaccine of claim 1, 5, or 6, wherein at least one of said regulatory sequences is the  
5 cytomagalovirus immediate-early enhancer promoter.

9. A DNA vaccine of claim 1, 5, or 6, wherein at least one of said regulatory sequences is intron A.

10. A DNA vaccine of claim 1, 5, or 6, wherein said rotavirus polypeptide is VP4.

10 11. A DNA vaccine of claim 1, 5, or 6, wherein said rotavirus polypeptide is VP6.

12. A DNA vaccine of claim 1, 5, or 6, wherein said rotavirus polypeptide is VP7.

13. A DNA vaccine of claim 1, 5, or 6, wherein  
15 said vertebrate is a pig.

14. A DNA vaccine of claim 1, 5, or 6, wherein said vertebrate is a human.

15. A DNA vaccine of claim 1, 5, or 6, wherein the DNA vaccine is formulated for administration to a  
20 vertebrate through a route of administration selected from the group consisting of inhalation, intravenous, intramuscular, intraperitoneal, intradermal, and subcutaneous.

SUBSTITUTE SHEET (RULE 26)

At risk of 16. A DNA vaccine of claim 1, 5, or 6, wherein the DNA vaccine is formulated for administration to a vertebrate by contacting the DNA vaccine with a mucosal surface of the vertebrate.

5 17. A DNA vaccine of claim 1, 5, or 6, wherein the DNA vaccine is microsphere encapsulated, and is formulated for administration to a vertebrate by contacting the microsphere-encapsulated DNA vaccine with a mucosal surface of the vertebrate.

10 18. A DNA vaccine of claim 1, 5, or 6, wherein the DNA vaccine is coated onto gold beads for administration to the vertebrate by particle bombardment delivery.

19. A DNA vaccine of claim 18, wherein the gold 15 beads are approximately 1  $\mu\text{m}$  to 2  $\mu\text{m}$  in diameter.

20. A DNA vaccine of claim 5 or 6, wherein the protective immunity is homologous, homotypic, heterotypic, or heterologous.

1/18




FIG. 1A



2/18




FIG. 1B

SUBSTITUTE SHEET (RULE 26)

3/18




FIG. 2

4/18




FIG. 3

SUBSTITUTE SHEET (RULE 26)

5/18




FIG. 4A




FIG. 4B

6/18




FIG. 5

7/18




FIG. 6

8/18




FIG. 7

9/18




FIG. 8



10/18




FIG. 9

11/18




FIG. 10

SUBSTITUTE SHEET (RULE 26)

12/18

Ew4  
MURINE Rotavirus  
VP4

1 ggctataaaa tggcttcact catttataga caactgctca cgaattcctt  
51 taccgtacat atatctgatg aaattgaaac tattggagca gagaagacac  
101 aaaatgttac agtgaatccc ggtccattcg cgcaaacggg atacgccccca  
151 gcaaactggg ggccaggcga aactaacgac tcaacaacag tagaaccaat  
201 gcttgatgga ccataccaac caatagcgtt cagtcgcgcg ccagagtact  
251 atatcatcct ctccccgact gcacccggag taatcgctga atgtacgaat  
301 actgtcaacc gctggatagc aatcatagct atagagccaa acgtgtcaac  
351 aacaaatcgt acctacacat tggtcgggaat tactgaacag ctaacagtag  
401 aaaacagctc cgtggataaa tggaagttaa tagacttcat gaaaactcca  
451 acaactggca gctacgtccg ttataacatt ttgttgtcta gcactaagct  
501 atgcgcagtg gcgaacgaca cggacaattt atactcctat gttggagaaa  
551 cgcctactgc aggtcaggca tactactcct ctttcaatat atttaaccta  
601 accgcgcact gtgacttcta cattatacca tggtcgcagc aatcgttgtg  
651 cacgcaatac gttaataacg gattaccgcc gatccagaat acaagaaatg  
701 tagtgccaag acatctgtca gcgagatcaa tcatcacaca aagagcgcaa  
751 cagaatgaag acattgttgt gtcaaagaca tccttatgga aagaaatgca  
801 gtttaatagg gacataacaa tacgtttcaa attcgcgaat gcaataataa  
851 agtctggcgg cttgggatat aattggtcag agatctcttt caaaccagcg  
901 aactaccaat acacgtacac acgtgatggg gaagaagtaa ctgcgcatac  
951 tacgtgctcg gtaaacggtg tgaacaactt cgatttcttt ggcggtacgc  
1001 tccctacgga tttcgggtatt tcgcggtacg aagtgattaa ggagaattca  
1051 ttcgtgtaca tagactattg ggacgactct caggccttca gaaatatggg  
1101 ctatgtgcgc tcactagcgg ctgatttgaa cactgtcgaa tgcactgggg  
1151 gggcgtacag cttttcacta ccagttgggc aatggccggg gatgacgggt  
1201 ggtgcagtg ctttgcgagc tgccggagtt acactateta cacagttcac

FIG. 11

13/18

1251 agacttcgtg tcgctaaatt cgttgagatt taggtttcgt ttgtcagtgg  
1301 aagaaccgtc attcagtata acgagaacaa gagtgtcagg gctatacggc  
1351 ttgccagagc gggatcctaa caacggcaga gaatattacg aaattgcagg  
1401 tagattttcg ttaatatcat tagtgccgtc caacgataac tatcaaacac  
1451 cgataatgaa ttcagttacg gtgcggcaag atctggagag acagctaggc  
1501 gaactacgac gagaattcaa cgcgctgtcg caggaaatag cgctgtcaca  
1551 gttggtggat ttagcgctac tgccattaga tatgttctca atgttttcag  
1601 gcatcaaagc aacgctcgac gtggcaaagt caatggcaac gaacgtgatg  
1651 aaaaaattca aaaaatcggg actggccacg tcgatttcac gcatgactga  
1701 gtcactatca gatgcagctt cctcagtgtc tcggagttag ctgcatacgc  
1751 tcagtcagtt ccacgtcatc agcttggaaca gacgtttcgt agctgctgtg  
1801 gccaacgtgg aaaatgccgc ctcaacagtt tcaacacaga cggccacaat  
1851 cagcagacgg ttgagactga aggaatcac aacgcagact gaaggcatga  
1901 acttcgatga catctcagcc gctgtactta aaactaagct tgataaatca  
1951 gtacgaatcg cgccgaacac getaccagac atagtaacag aagcgtcaga  
2001 gaagttcatt ccgaacagat catacagagt tataaacaac aatgaagcat  
2051 tcgaaactgg aactgacgga cgcttcttcg cataccgagt tgacactctt  
2101 gaggaactgc cattcgacgt tcagaaatte gcatgccatg ctgcagagtc  
2151 cccagtaatc tcagccatca ctgacttcaa gactttgaaa aatttgaacg  
2201 ataactacgg aatctcgaaa gaacaggcct tcagtttatt acgctcagat  
2251 ccgcgagtac tccgtgaatt tattaatcag gggaatccaa taatacgtaa  
2301 tagaatagaa cagttaatta tgcagtgtag actgtgagca gtgtctagag  
2351 gatgtgacc (SEQ ID NO: 1)

FIG. 11A

SUBSTITUTE SHEET (RULE 26)

Human Rotavirus  
VP4

14/18

1 GGCTATAAAATGGCTTCGCTCATTATAGACAGCTTCTCACTAATTCATA  
51 TTCAGTAGATTACATGATGAAATAGAGCAAATTGGGTGAGAAAAAATC  
101 AAAACGTAACTGTAAATCCAGGTCCATTGCCCCAACTAGATATGCTCCA  
151 GTAAATTGGGGTCATGGAGAGATAAATGATTCAACCAAGTAGAAACCAAT  
201 TTTAGATGGTCCTTATCAGCCTACTACATTTAAACCACTTACTGATTATT  
251 GGATACCTTATTAACCTCAAATACAAATGGAGTGGTATACGAGAGTACGAAT  
301 AATAGTGACTTTTGGACTGCAGTAGTTGCTATTGAAACCGCAGTTATCCA  
351 AGTAGATAGACAATATACTGTATTGTTGGTGAATAAACAATTTAATGTAA  
401 GAAATGATTGAGATAAATCGAAGTTTTAGAAATGTTTAGAGGCAGTAGT  
451 CAAAATGAATTTTATAATAGACGTACACTAACTTCTGATACTAACTCGT  
501 AGGAATATTAAATATGGTGGAGGATATGGACATTTTCATGGTGAACAC  
551 CGAGAGCTACTACTGATAGTTCAAACTACTGCAAATTTAAACGATATATCA  
601 ATTATAATACATTGAGAATTTTATATTATCCCAAGGTCCCAAGAATCTAA  
651 GTTAATGAATATATTAAATGTTTGGTGGTCCCAATTTCAAAATAGTAA  
701 ATGTAGTACCATTATCATTATCATCTAGATCCATACAGTATAAAGAGCA  
751 CAACTTAATGAAGATATTACAATTTCAAAAACCTCATTATGGAAGAAAT  
801 CCAATGTAATAGGGATATTATAATTAGATTTAAATTTGGTAATAGTATTG  
851 TAAACTGGGGGGAGTAGGTTATAAATGGTCCGAAATATCATATAAAGCA  
901 GCAATTTATCAATATAATTATCTACGTGATGGCGAACAAGTAACGACACA  
951 TACTACTTGGCTCAGTAAATCGAGTAAATAATTTTACCTACACCCAGCAT  
1001 CTTTACCTACTCATTTTAGTGTCTCAAGGTATGAAGTTATTAAAGAAAAT  
1051 TCTTATGTATATGTAGATTATTGCGATCATTCAAAAGCATTTAGAAATAT  
1101 GGTATATGTCAGATCATTAGCAGCTAATTTGAACTCAGTGAATGTACAG  
1151 CTCCAACTTATCCTTTAGTATACCTGTAGGTGCATGGCCAGTCATGAAT  
1201 GGTGGCGCTGTTTCGTTGCATTTTGTGGAGTTACATTATCTACGCAATT  
1251 CACAGATTTGCTATCATTCAATTGACTACCATTTAGATTTACTTTGACAG  
1301 TGGATGAGCCATCTTTTTCAATATTGAGAACACGTACGGTGAATTTGTAC  
1351 GGATTACCAGCTGCAAAATCCAAATAATGGAATGAATCTATGAATATC  
1401 AGCAAGCTTTTCGCTCATTTCTTTACTTCCAACTAATCATCATTATCAGA  
1451 CTCCAATTATGAATTCAGTAACAGTAAGAGAAGATTTAGAACGTCAACTT  
1501 ACTCATTTACCAGACCAATTTAATTCATTATCACAAGAAATAGCTATGTC  
1551 ACAATTAATTGATTTAGCGTTATTACCTTTAGATATGTTTTCTATGTTTT  
1601 CGGAATTAAGTACAAATTTGATTTGACTAAATCAATGGCACTAGTGTA  
1651 ATGAATAATTTAGAAATCAAAATTTACCTACATCAATTTACAGAAATGAC  
1701 TCATTCAATTGTCAGACGCAGCATCATCAGCATCAAGAAGCGTTTCTATCA  
1751 GATCGAATATATCCCAATTTCCAAATGGACTAATGTTTCMAATGATGTA  
1801 TCAAAATGTGACTAAATTCGTTGAGTGATATTTCAACACAAACGTCTACAAT  
1851 CAGTAAGAACCCTTAGATTAAAGAAATGATTACTCAAACTGAAGGAATGA  
1901 GTTTTGCATGATTTTCAGCGGCAGTATTAAAAACAAATACATATCTCT  
1951 ACTCAATTTGGAAAGAAATACCTTTACCCGATATAGTCACAGAGGCATCTGA  
2001 GAAATTTATTCMAAAACCATCTATCCAAATATTCAAAGATCATCAACTAA  
2051 TGGAAATTAATCTGAAGGGAAAGTCTTTGCATATAAAATCGACACACTT  
2101 AATGAAGTGCCATTGATGTAAATAAATTTGCTGAACCTGTAACAAATTC  
2151 TCCAGTTATATCAGCAATAATCGATTTTAAACATTAAAAATTTCAATC  
2201 ATAAATTAAGAAATTAATCGAATAGAGCATTAAATTTAATTAAATCGAAT  
2251 CCAATGTATTACGTAATTTTATTAAACCAAAATTAATCCAATTATAACGAA  
2301 TAGAATTAAGACAGCTAAATTTCTACAATGTAATTTGTGAGAACGCTATTGAG  
2351 GATGTGACC (SEQ ID NO: 5)

FIG. 12

SEQUENCE LISTING

15/18

## Human Rotavirus

## VP6

-----+-----,-----+-----,-----+-----,-----+-----,-----+-----  
1 GGCTTTAAACGAAGTCTTCGACATGGAGGTTCTGTATTTCATTGTCAAAA  
51 ACTCTTAAAGATGCTAGGGATAAGATTGTTGAAGGTACATTATATTCTAA  
101 TGTTAGTGATCTCATTTCAGCAATTTAATCAAATGATAGTAACCATGAATG  
151 GAAATGACTTTCAAACCTGGAGGAATTGGCAATTTACCTATTAGAAATTGG  
201 ACATTTGACTTTGGTCTACTAGGTACTACGCTGTTAAACCTTGATGCTAA  
-----+-----,-----+-----,-----+-----,-----+-----,-----+-----  
251 TTACGTTGAGACTGCAAGAACTACAATTAAGTATTTTATTGACTTTATTG  
301 ATAATGTATGTATGGATGAAATGGCAAGAGAGTCTCAAAGAAATGGAGTA  
351 GCTCCACAATCTGAGGCATTGAGGAAGCTAGCCGGTATTAAATTTAAAG  
401 AATAAATTTTAATAATTATCAGAAATATATAGAAAATTGGAATTTACAAA  
451 ATAGAAGACAGCGTACCGGATTGTTTTCCATAAACCTAATATATTTCCA  
-----+-----,-----+-----,-----+-----,-----+-----,-----+-----  
501 TACTCAGCATCATTTACTTTAAATAGGTCTCAACCAATGCATGACAATTT  
551 AATGGGAACCATGTGGCTTAACGCTGGATCAGAAATTCAAGTGGCTGGAT  
601 TTGACTACTCGTGTGCCCTAAATGCTCCAGCAAATATTTCAGCAGTTGAA  
651 CATATTGTCAGCTTAGGCGTGCGCTAACTACAGCTACTATAACTTTGCT  
701 ACCTGATGCAGAAAGATTTAGTTTTCCAAGAGTTATTAATTCAGCAGATG  
-----+-----,-----+-----,-----+-----,-----+-----,-----+-----  
751 GCGCAACCACATGGTTCTTTAATCCAATTATCCTAAGACCAAACAATGTA  
801 GAGGTAGAATTTTACTGAATGGACAAATTATTAATACATATCAAGCTAG  
851 ATTTGGAATATTATCGCAAGAAATTTTGATACAATTCGTCTATCATTC  
901 AATTAAATGCGTCCACCAAACATGACGCCAGCCGTAAATGCATTATTTCCG  
951 CAAGCACAACTTTTCAACATCATGCAACAGTTGGACTTACGTTACGTAT  
-----+-----,-----+-----,-----+-----,-----+-----,-----+-----  
1001 TGAGTCTGCACTTTGTGAATCAGTGCTTGCGGATGCAAATGAACTTTAT  
1051 TGGCGAATGTTACTGCAGTACGTCAAGAGTATGCTATAGGCGTTGGACCA  
1101 GTATTTCCACCAGGCATGAATTGGACTGAGCTGATTACTAACTATTCACC  
1151 ATCCAGGGAAGATAATTGCAACGTGTCTTTACAGTAGCCTCTATCAGAA  
1201 GCATGTTAATTAAGTGAGGACCAGACTAACCATCTGGTATCCAATCTTAA  
-----+-----,-----+-----,-----+-----,-----+-----,-----+-----  
1251 TTAGCATGTAGCTATGTCAAGTCATTTCAGACTCTACAAGTAAGGACATGA  
1301 TTTATGTTTCGCTACGTAGAGTAAGTGCATGAATGATCTAGTGAGAGGAT  
1351 GTGACC (SEQ ID NO: 2)

FIG. 13

16/18

Bovine Rotavirus  
VP6

-----+-----+-----+-----+-----+-----+-----+  
1 GGCTTTTAAACGAAGTCTTCAACATGGATGTCCTGTACTCCTTGTCAAAA  
51 ACTCTTAAAGATGCTAGAGACAAAATTGTCGAAGGCACATTATACTCCAA  
101 TGTAAGTGATCTAATTCAACAATTTAATCAAATGATAATTACTATGAATG  
151 GAAATGAGTTCCAAACTGGAGGAATTGGTAATCTACCGATTAGAAATTGG  
201 AATTTTGATTTTGGATTACTCGGAACAACTCTACTAAATTTGGATGCCAA  
-----+-----+-----+-----+-----+-----+-----+  
251 CTACGTCGAAACGGCCCGCAATACAATTGATTATTTTGTAGATTTTGTAG  
301 ATAATGTATGTATGGATGAAATGGTTAGAGAATCACAAAGAAATGGAATT  
351 GCACCACAATCAGATTCAGTTCACTTAGAAAAGTTGTCAGGTATTAAATTCAAAAG  
401 AATAAATTTTGACAATTCATCAGAATACATAGAGAACTGGAATTTGCAA  
451 ACAGAAGACAAAGAACGGGTTTTACATTTTCATAAACCAACATTTTCCCT  
-----+-----+-----+-----+-----+-----+-----+  
501 TACTCAGCGTCATTCACTGAACAGATCACAACCAGCTCATGATAACTT  
551 GATGGGTACGATGTGGCTCAATGCGGGATCAGAAATTCAGGTGCGTGGAT  
601 TCGATTATTCATGTGCAATCAATGCGCCAGCCAATACACAACAATTTGAG  
651 CATATTGTACAGCTCCGAAGAGTGTGACTACAGCTACAATAACTCTTTT  
701 ACCAGATGCAGAAAGATTTAGTTTTCCAAGAGTGATTAATTCAGCTGACG  
-----+-----+-----+-----+-----+-----+-----+  
751 GAGCTACTACATGGTACTTCAACCCAGTGATTCTTAGACCAAATAACGTT  
801 GAAGTAGAGTTTCTACTAAACGGGCAGATAATAAATACTTACCAAGCAAG  
851 ATTTGGAACGATCATAGCTAGAAATTTTGATACAATTAGATTGTCATTTT  
901 AGTTGATGAGACCACCAAATATGACACCAGCGGTAGCGGCGTTATTTCCA  
951 AATGCGCAGCCATTTGAACATCAGGCAACAGTAGGACTCACGCTTAGAAT  
-----+-----+-----+-----+-----+-----+-----+  
1001 TGAATCTGCAGTTTGTGAATCAGTGCTTGCCGACGCAAGTGAAACAATGC  
1051 TAGCAAATGTGACATCTGTTAGACAAGAATACGCGATACCAGTTGGACCA  
1101 GTTTTTCACCAGGTATGAATTGGACTGATTTGATCACTAACTATTACCC  
1151 ATCTAGAGAGGATAATTTGCAGCGTGTATTTACAGTGGCTTCCATTAGAA  
1201 GCATGCTTGTCAAATGAGGACCAAGCTAACCCTTGGTATCCGACTTTGG  
-----+-----+-----+-----+-----+-----+-----+  
1251 TGAGTATGTAGCTACGTCAAGCTGTTTGAACCTCTGTAAGTAAGGATGCGT  
1301 CTACGTATTCGCTACACAGAGTAATCACTCAGATGGCGTAGTGAGAGGAT  
1351 GTGACC (SEQ ID NO: 3)

FIG. 14

SUBSTITUTE SHEET (RULE 26)

EW VP7

17/18

Murine Rotavirus  
VP7

GGCTTTAAAGAGAGAATTTCCGTTTGGCTAGCGGTTAGCTCCTTTTAATGTATGGTATT 60  
GAATATACCACAGCTTTAACTTTCTGATATCATTTCCTTTATTGCGCTACATACTAAAA 120  
TCAGTAGTTAAAAATTATGGACTTTATAGTTTACAGGTTTTTGTGTTGTAATTCTAATTTTG 180  
TCGCCATGTATTAAAGCTCAAACTACGGCATTAACTCTTCCAATTACTGGTTCAATGGAC 240  
ACTGCGTATGCAAACTCAACTCAACCGGAGACATTTCTGACTTCCACTCTATGCCTTTAC 300  
TATCCAACAGAAGCAGCTACTGAGATAAAGGATAACTCGTGGAAGACACGTTATCGCAA 360  
CTATTCTTAACGAAAGGATGGCCAATAGGGTCAGTCTATTTTAAAGAATACACCGACATA 420  
GCAGCGTTCTCAATCGATCCACAACCTATACTGTGATTACAACGTAGTGCTGATGAAATAT 480  
GACGCTTCATTACAAATGGATATGTCGGAACCTGCAGACTTGATACTGAATGAATGGCTT 540  
TGTAATCCAATGGACATCAGCTATACTACTACCAGCAAACAGACGAAGCGAACAATGG 600  
ATCTCCATGGGCTCTTCATGTACCATCAGAGTATGTCCACTTAACACTCAGACACTGGGA 660  
ATAGGCTGTCTCACTACCGATGTTACGACCTTCGAAGAAATTGCGACTGCCGAGAAATTA 720  
GCGATAACGGACGTCGTAGATGCGCTGAGTCACAAGCTTAACGTTACAACCGCGACTTGT 780  
ACAATTCGTAACCTGTAAGAACTTGGTCCCGGAGAAAATGTAGCAGTTATACAAGTAGGT 840  
GGCTCTGACATAATAGACATAACTGCAGATCCAACAACCTGCACCACAAACCGAGAGAATG 900  
ATGCGCATTAAATTGGAAAAAATGGTGGCAAGTGTCTACACCGTCGTTGATTATGTAAAT 960  
CAGATAATCTCAACAATGTCCAAACGATCTAGATCACTGAACTCAGCAGCTTTTTATTAT 1020  
AGAGTGTAGGTATAACTGAAGTTACAGCTGATGATGTGACC (SEQ ID NO: 4)

FIG. 15

SUBSTITUTE SHEET (RULE 26)



18/18

Human Rotavirus  
VP7

```
-----+-----+-----+-----+-----+-----+
1  GGCTTTAAAAGAGAGAATTTCCGCTCTGGCTAGCGGATAGCTCCTTTTAAT
51  GTATGGTATTGAATATACCACAGTTCTATTTTATTTGATATCGTTCGTTTC
101 TTGTGAGTTATATTCTGAAAACCATAATAAAGATAATGGACTATATTATT
151 TATAGAATAGCATTGTGTAATTGTAGTATTATCAGTATTATCGAATGCACA
201 AAATTATGGAATAAATTTGCCAATTACTGGATCTATGGATACAGCATATG
-----+-----+-----+-----+-----+-----+
251 CTAACCAACACAAGACAATAATTTTTTAGTTTCAACTTTATGCTCTATAT
301 TATCCATCAGAAGCTCCAACCTCAAATTAGTGACACTGAATGGAAAGATAC
351 ACTATCTCAGCTGTTTTTAACCAAGGATGGCCGACAGGTTTCAGTTTATT
401 TTAATGAATATTCAAACGTTTTAGAAATTTCCATCGACCCAAAGCTATAC
451 TGTGATTATAATGTTGTGCTAATTAGATTTCGTTTCTGGTGAGGAGTTGGA
-----+-----+-----+-----+-----+-----+
501 CATATCTGAATTAGCTGATCTAATACTGAATGAGTGTTATGTAATCCAA
551 TGGATATAACATTATATTATTACCAACAAACTGGAGAGGCAACAAATGG
601 ATATCAATGGGATCATCATGTACCGTTAAAGTGTGTCCATTAAATACTCA
651 GACATTAGGAATTGGATGTCAAACGACAAATACAGCTACTTTTGAAACAG
701 TTGCTGATAGCGAAAAATTGGCAATAATTGATGTTGTCTACATCGTAAAT
-----+-----+-----+-----+-----+-----+
751 CATAAATTAAATATCACATCTACTACATGTACAATACGGAATTGTAATAA
801 ACTAGGACCGAGAGAAAATGTGGCTATAATACAGGTTGGCGGTTCTAATA
851 TATTAGATATAACAGCTGATCCCACAACTTCTCCACAAACAGAACGAATG
901 ATGCGCGTAAACTGGAAAAAATGGTGGCAAGTATTCTACACTGTAGTTGA
951 TTACATTAATCAGATAGTACAAGTAATGTCCAAAAGATCAAGATCGTTAG
-----+-----+-----+-----+-----+-----+
1001 ATTCGTCAGCTTTCTATTATAGAGTGTAGATATATCCTAAAATAGAAGTG
1051 TTTGATGTGACC (SEQ ID NO: 6)
```

FIG. 16

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US95/09470

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 31/00

US CL : 514/44

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/44

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE, EMBASE, BIOSIS, CAPLUS, APS

search terms: rotaviru?, vaccina?, immuniz?, plasmid?, vp4, vp6, vp7, dna, microspher?

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO, A, 92/07941 (UNIVERSITY OF SASKATCHEWAN) 14 MAY 1992, see entire document.	1-20
Y	VACCINE, Vol. 12, No. 16, issued 1994, Davis et al, "Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against the hepatitis B virus surface antigen", pages 1503-1509, see entire document.	1-20
Y	Proceedings of the National Academy of Sciences USA, Vol. 90, issued December 1993, Fynan et al, "DNA vaccines: Protective immunizations by parental, mucosal, and gene-gun inoculations", pages 11478-11482, see entire document.	1-20

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

Special categories of cited documents:	
*A* document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*E* earlier document published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*O* document referring to an oral disclosure, use, exhibition or other means	*Z* document member of the same patent family
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

21 SEPTEMBER 1995

Date of mailing of the international search report

25 OCT 1995

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Authorized officer

D. CURTIS ROGUE, JR

Facsimile No. (703) 305-3230

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)\*

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	VACCINE, Vol. 12, No. 16, issued 1994, Cichutek, Peter, "Nucleic acid immunization: a prophylactic gene therapy?", pages 1520-1525, see entire document.	1-20
Y	VACCINE, Vol. 12, No. 16, issued 1994, Ulmer et al, "Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines", pages 1541-1544, see entire document.	1-20
Y	VACCINE, Vol. 12, No. 16, issued 1994, Webster et al, "Protection of ferrets against influenza challenge with a DNA vaccine to the haemagglutinin", pages 1495-1498, see entire document.	1-20
Y	HUMAN GENE THERAPY, Vol. 5, issued November 1994, Katsumi et al, "Humoral and Cellular Immunity to an Encoded Protein Induced by Direct DNA Injection", pages 1335-1339, see entire document.	1-20
Y	NATURE, Vol. 356, issued 12 March 1992, Tang et al, "Genetic immunization is a simple method for eliciting an immune response", pages 152-154, see entire document.	1-20

2000-2000

2000

2000-2000

2000-2000

2000-2000